A citation-based method for searching scientific literature

Joaquin Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, Mark Davies, Elena Garralda, Jan Geissler, Don Husereau, Iciar Martinez-Lopez, Nicola Normanno, Jorge S Reis-Filho, Stephen Stefani, David M Thomas, C Benedikt Westphalen, Emile Voest. Nat Med 2022
Times Cited: 11







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
27

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro,[...]. Lancet Oncol 2022
22
18

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
18

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong,[...]. N Engl J Med 2019
516
18

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
457
18

Review of precision cancer medicine: Evolution of the treatment paradigm.
Apostolia M Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock. Cancer Treat Rev 2020
95
18

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
641
18

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
258
18

The evolutionary dynamics and fitness landscape of clonal hematopoiesis.
Caroline J Watson, A L Papula, Gladys Y P Poon, Wing H Wong, Andrew L Young, Todd E Druley, Daniel S Fisher, Jamie R Blundell. Science 2020
149
18

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
856
18

Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Nicola Normanno, Kathi Apostolidis, Francesco de Lorenzo, Philip A Beer, Raymond Henderson, Richard Sullivan, Andrew V Biankin, Denis Horgan, Mark Lawler. Semin Cancer Biol 2022
6
33

Precision Medicine in Phaeochromocytoma and Paraganglioma.
Bettina Winzeler, Benjamin G Challis, Ruth T Casey. J Pers Med 2021
1
100

Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature.
Camille Duhamel, Mirela Diana Ilie, Henri Salle, Adjoa Sika Nassouri, Stephan Gaillard, Elise Deluche, Richard Assaker, Laurent Mortier, Christine Cortet, Gérald Raverot. J Pers Med 2020
19
9


What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.
Vittoria Basile, Soraya Puglisi, Barbara Altieri, Letizia Canu, Rossella Libè, Filippo Ceccato, Felix Beuschlein, Marcus Quinkler, Anna Calabrese, Paola Perotti,[...]. J Pers Med 2021
6
16


Next-generation therapies for adrenocortical carcinoma.
Barbara Altieri, Cristina L Ronchi, Matthias Kroiss, Martin Fassnacht. Best Pract Res Clin Endocrinol Metab 2020
40
9

Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies.
Anna Angelousi, Georgios K Dimitriadis, Georgios Zografos, Svenja Nölting, Gregory Kaltsas, Ashley Grossman. Endocr Relat Cancer 2017
10
10

Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications.
Marco Volante, Ida Rapa, Jasna Metovic, Francesca Napoli, Cristian Tampieri, Eleonora Duregon, Massimo Terzolo, Mauro Papotti. J Pers Med 2021
2
50

Needs, Preferences, and Values during Different Treatment Decisions of Patients with Differentiated Thyroid Cancer.
Anna Koot, Romana Netea-Maier, Petronella Ottevanger, Rosella Hermens, Peep Stalmeier. J Pers Med 2021
1
100

Integrated genomic characterization of adrenocortical carcinoma.
Guillaume Assié, Eric Letouzé, Martin Fassnacht, Anne Jouinot, Windy Luscap, Olivia Barreau, Hanin Omeiri, Stéphanie Rodriguez, Karine Perlemoine, Fernande René-Corail,[...]. Nat Genet 2014
413
9

New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Matthew D Ringel. J Clin Endocrinol Metab 2021
6
16

Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
Siyuan Zheng, Andrew D Cherniack, Ninad Dewal, Richard A Moffitt, Ludmila Danilova, Bradley A Murray, Antonio M Lerario, Tobias Else, Theo A Knijnenburg, Giovanni Ciriello,[...]. Cancer Cell 2016
322
9

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer.
Tiziana Feola, Alessia Cozzolino, Roberta Centello, Carla Pandozzi, Maria Grazia Tarsitano, Elisa Giannetta. J Pers Med 2021
3
33

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.
Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari. J Pers Med 2021
2
50

The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms.
Anna Angelousi, Georgios Kyriakopoulos, Fani Athanasouli, Anastasia Dimitriadi, Eva Kassi, Chrysanthi Aggeli, George Zografos, Gregory Kaltsas. J Pers Med 2021
2
50


Metformin and reduced risk of cancer in diabetic patients.
Josie M M Evans, Louise A Donnelly, Alistair M Emslie-Smith, Dario R Alessi, Andrew D Morris. BMJ 2005
9

A quantitative analysis of kinase inhibitor selectivity.
Mazen W Karaman, Sanna Herrgard, Daniel K Treiber, Paul Gallant, Corey E Atteridge, Brian T Campbell, Katrina W Chan, Pietro Ciceri, Mindy I Davis, Philip T Edeen,[...]. Nat Biotechnol 2008
9

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A Margolin, Sungjoon Kim, Christopher J Wilson, Joseph Lehár, Gregory V Kryukov, Dmitriy Sonkin,[...]. Nature 2012
9


Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
9

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
9

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
9

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Vinod A Pullarkat, Norman J Lacayo, Elias Jabbour, Jeffrey E Rubnitz, Ashish Bajel, Theodore W Laetsch, Jessica Leonard, Susan I Colace, Seong Lin Khaw, Shaun A Fleming,[...]. Cancer Discov 2021
49
9

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M Corsello, Rohith T Nagari, Ryan D Spangler, Jordan Rossen, Mustafa Kocak, Jordan G Bryan, Ranad Humeidi, David Peck, Xiaoyun Wu, Andrew A Tang,[...]. Nat Cancer 2020
157
9

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.
João M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N Ooft, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang,[...]. Nat Commun 2020
37
9

Clinical development success rates for investigational drugs.
Michael Hay, David W Thomas, John L Craighead, Celia Economides, Jesse Rosenthal. Nat Biotechnol 2014
9

Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.
Paul E Harrington, Kaustav Biswas, David Malwitz, Andrew S Tasker, Christopher Mohr, Kristin L Andrews, Ken Dellamaggiore, Richard Kendall, Holger Beckmann, Peter Jaeckel,[...]. ACS Med Chem Lett 2014
58
9

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Vito Amodio, Rona Yaeger, Pamela Arcella, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato, Sabrina Arena, Monica Montone, Benedetta Mussolin, Yu Bian,[...]. Cancer Discov 2020
114
9

High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Kristiina Iljin, Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka Kohonen, Vidal Fey, Roland C Grafström, Merja Perälä, Olli Kallioniemi. Clin Cancer Res 2009
137
9

The target landscape of clinical kinase drugs.
Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm, Harald Polzer, Binje Vick, Paul-Albert Koenig, Maria Reinecke, Benjamin Ruprecht, Svenja Petzoldt, Chen Meng,[...]. Science 2017
395
9

A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Hovav Nechushtan, Yousef Hamamreh, Salim Nidal, Maya Gotfried, Amichai Baron, Yossi Israeli Shalev, Benjjamin Nisman, Tamar Peretz, Nili Peylan-Ramu. Oncologist 2015
96
9

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, John P Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi-Lin Chiu,[...]. Lancet Oncol 2010
546
9

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Erin F Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis Worden, David C Smith, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva,[...]. JAMA Oncol 2021
38
9


Thalidomide-induced teratogenesis: history and mechanisms.
Neil Vargesson. Birth Defects Res C Embryo Today 2015
326
9

Metformin in cancer prevention and therapy.
Jacek Kasznicki, Agnieszka Sliwinska, Józef Drzewoski. Ann Transl Med 2014
244
9


Tumour-agnostic therapies.
Ann-Marie Looney, Khurram Nawaz, Rachel M Webster. Nat Rev Drug Discov 2020
23
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.